<DOC>
	<DOC>NCT00300508</DOC>
	<brief_summary>The study assesses the effect of a further 3 years adjuvant treatment with anastrozole vs. an untreated control group after initial 5 years of adjuvant hormone-therapy.</brief_summary>
	<brief_title>3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>No disease recurrence at time of randomization, patients with breast cancer after surgery, 5 years (+/ 12 months) of prior endocrine therapy Premenopausal patients, unknown or negative receptor status, Secondary malignant tumor</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Hormone receptor positive breast cancer</keyword>
</DOC>